Today: 7 November 2025
Subscribe
Browse Category

Investing News 11 October 2025 - 12 October 2025

US Antimony (UAMY) Stock Skyrockets on $245M Defense Deal – Is It Too Good to Be True?

US Antimony (UAMY) Stock Skyrockets on $245M Defense Deal – Is It Too Good to Be True?

Company Background United States Antimony Corp. is a Texas-based critical-minerals developer specializing in antimony – a silvery metal used to harden lead (e.g. bullets), produce flame-retardants and advanced battery alloys. The company was founded decades ago and today owns and operates the only two antimony smelters in North America mining.com. Its Montana and Mexican facilities process raw antimony ore into oxide, metal and trisulfide for industrial and military customers, and also recover zeolite and precious metals as byproducts. U.S. Antimony’s board recently added national security expert General Jack Keane, underscoring its strategic mission usantimony.com. In mid-2025 the company shifted its
12 October 2025
 ·  ·  ·  ·  · 
Is 3M Stock Poised for a Comeback? Key Facts & Analysts’ Take (Oct 2025)

Is 3M Stock Poised for a Comeback? Key Facts & Analysts’ Take (Oct 2025)

Figure: 3M’s headquarters in Maplewood, MN. Despite legal overhang, management has launched a “3M eXcellence” program to cut costs and drive innovation investing.com nasdaq.com. Stock Price & Recent Performance MMM shares trade around $149 as of Oct 10, 2025 ts2.tech. After rallying earlier in the year, the stock has pulled back in October. On Oct 10 it closed at $148.75 ts2.tech, down 2.7% on the day and about 6.4% below the prior week ts2.tech. The 52-week range is roughly $122–$164 ts2.tech, with year-to-date gains of about +10%. Volume has been moderate and volatility is near market average (3M’s beta ~1.05
12 October 2025
 ·  ·  ·  ·  · 
AI Ignites a Nuclear Renaissance: How Tech Titans, Policy Shifts and New Reactors Are Powering the Next Energy Revolution

Cameco vs. Oklo: Which Nuclear Stock Will Ignite Your Portfolio?

Nuclear’s Second Act: Clean Power Gains Momentum After decades of stagnation, nuclear power is enjoying a dramatic comeback. In 2024–2025, dozens of governments have either restarted plants or greenlit new ones to meet climate and energy-security goals. The U.S. Congress funneled record funding into nuclear R&D and fuel (doubling enrichment and building HALEU supply) as part of a clean-energy spending bill energy.gov energy.gov. Likewise, Congress passed bipartisan laws (the 2024 ADVANCE Act) to speed up licensing of new reactor designs nrc.gov. Globally, countries from France and the UK to China, India, and even some historically anti-nuclear nations (Italy, Serbia, etc.)
12 October 2025
 ·  ·  ·  ·  ·  · 
AI Frenzy Fuels Record Wall St Rally as Shutdown Drags On – Key Market News (Oct 6-7, 2025)

Stock Market Today 12.10.2025

Sorkin warns: Stock market shows 1929-like signs amid AI boom October 12, 2025, 7:53 PM EDT. Financial journalist Andrew Ross Sorkin warns that today’s Wall Street mirrors the 1929 era, where highs preceded a devastating crash. He credits an AI- and technology-driven boom for recent gains but cautions it may be a temporary sugar rush rather than a durable recovery. Valuations, he suggests, could be overpriced and markets may be riding a fragile buoyancy. The piece contrasts today’s surge with the 1920s’ rapid credit expansion, including buying on margin, that helped fuel speculative excess. Sorkin says a crash is likely,
12 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Visa (V) Stock Poised for a Surge? Crypto Pilot and Travel Deals Fuel Optimism

Visa (V) Stock Poised for a Surge? Crypto Pilot and Travel Deals Fuel Optimism

Stock Price and Recent Performance Visa trades under the ticker V on the NYSE. After markets closed on Friday, Oct 10, 2025, Visa was about $343.65 investor.visa.com per share, down ~$3 (roughly 1%) on the day. (Its intraday range was roughly $343–$350.) Earlier in the week, the stock dipped to a new 2025 low when the DOJ antitrust news broke ainvest.com. Year-to-date (Jan–Oct 2025), Visa’s stock is up on the order of 10–12%. For context, Reuters reported that by late July Visa was up ~13% for the year, versus +8% for Mastercard and –10% for AmEx reuters.com. By late July,
11 October 2025
 ·  ·  ·  ·  · 
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025 marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50 investing.com. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into the low-$230s as investors digest upcoming FDA news. On Oct. 1 the entire pharma sector rallied (+5% in Europe) after Pfizer announced a U.S. drug-pricing deal reuters.com; AbbVie’s shares jumped ~6–8% that day as well. Technicals (50-day MA ≈ $214; 200-day
11 October 2025
 ·  ·  ·  ·  · 
CNQ Stock Skyrocketing? Oil Rally, 25-Year Dividends & Expert Forecasts (Oct 2025)

CNQ Stock Skyrocketing? Oil Rally, 25-Year Dividends & Expert Forecasts (Oct 2025)

CNQ Stock Price & Recent Performance CNQ’s stock has climbed in recent weeks. The TSX-listed share reached ~C$45.55 on Oct 9 simplywall.st (about $31.40 on NYSE). This is near its 3-year high (∼C$48), though still below the 2023 peak (~C$52). Over the last week it gained ~3% simplywall.st, driven by a bounce in oil prices and positive sentiment. For context, CNQ is up ~45% over 3 years and nearly +400% over 5 years simplywall.st, illustrating its strong long-term return. In intraday action on Oct 10, CNQ did fall (~4%) on heavy volume, partly reflecting a broad market selloff oilprice.comand some specific
11 October 2025
 ·  ·  ·  ·  · 
3M Stock Set to Soar! PFAS Settlement and Dividends Spark Rally (Oct 2025)

3M Stock Set to Soar! PFAS Settlement and Dividends Spark Rally (Oct 2025)

Stock Price & Recent Performance 3M’s stock has been trading in the low-to-mid $150s this autumn. As of Oct 10, 2025, it closed near $148.75 tradingview.com. That day’s drop (~–2.7%) came amid broad market pullback. Over the past week MMM has slid roughly –6.4% tradingview.com, reversing part of its earlier gains. (Year-to-date MMM was up ~10.6% tradingview.com, roughly in line with the S&P 500.) The 52-week trading range is about $122–$164, with 50-day and 200-day moving averages near $154 and $149 respectively marketbeat.com. Technical indicators show MMM recently lost some momentum. Chart analysis highlights a support zone around $146–147 and resistance near $156–167. For example, AI-driven
11 October 2025
 ·  ·  ·  ·  · 
Coca-Cola (KO) Stock: 7 Surprising Facts You Need to Know (Oct 11, 2025)

Coca-Cola (KO) Stock: 7 Surprising Facts You Need to Know (Oct 11, 2025)

Figure: A Coca-Cola distribution truck in downtown Los Angeles (2018). The company’s products are delivered globally. Coke sells roughly 2 billion servings per day (over 700 million ounces) worldwide. It is a Dow-30 component and one of the largest non-alcoholic beverage companies. In emerging markets, KO often drives growth (e.g. Coca-Cola and local brands like Thums Up achieved double-digit volume growth in India investors.coca-colacompany.com). Figure: Coca-Cola products (Coke, Sprite, etc.) on the shelf of a Sarajevo supermarket (Bosnia, 2024). The brand’s retail presence spans countless stores globally. Sources: Authoritative analyses and news (Reuters, MarketBeat, SimplyWallSt, TS2.Tech, Motley Fool, etc.) have been used throughout this report
11 October 2025
 ·  ·  ·  ·  · 
Uranium Energy Corp (UEC) Stock Skyrockets on Nuclear Boom – Key Facts & Outlook

Uranium Energy Corp (UEC) Stock Skyrockets on Nuclear Boom – Key Facts & Outlook

Overview of Uranium Energy Corp (UEC) Uranium Energy Corp is a U.S.-based uranium mining and exploration company founded in 2003 (NYSE American: UEC). Headquartered in Corpus Christi, Texas, UEC has become “America’s largest and fastest growing supplier of uranium” for nuclear energy prnewswire.com. The company’s business model focuses on low-cost in-situ recovery (ISR) mining in the United States and high-grade conventional uranium projects in Canada prnewswire.com. This two-pronged approach lets UEC rapidly develop domestic uranium sources while also holding stakes in some of the world’s richest uranium districts. UEC operates on a “hub-and-spoke” strategy for ISR production. It has three
11 October 2025
 ·  ·  ·  ·  · 
Robinhood’s Wild 2025 Ride: HOOD Stock Skyrockets 200%, Plunges 9% in a Day – What’s Next?

Robinhood’s Wild 2025 Ride: HOOD Stock Skyrockets 200%, Plunges 9% in a Day – What’s Next?

HOOD Stock Price and Recent Performance Robinhood’s stock has been on a rollercoaster in 2025. After starting the year at much lower levels, HOOD nearly tripled in value by early October. On October 6, shares hit a record intra-week high around $153. But by the week’s end, the stock pulled back sharply, closing at $138.96 on Oct 10 after an 8.9% single-day plunge ts2.tech. (The Oct 10 drop coincided with a broader market selloff sparked by renewed U.S.–China trade war fears, which particularly hit high-growth tech stocks ts2.tech.) Even after the pullback, Robinhood remains up over 200% year-to-date, vastly outperforming
11 October 2025
 ·  ·  ·  ·  · 
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

(Source: Nasdaq/GlobeNewswire, Reuters, TipRanks, Finviz, company filings.) Company Overview: Rare Disease Focus and Pipeline Progress Quoin Pharmaceuticals Ltd. is a clinical-stage biotech specializing in rare dermatological diseases. Headquartered in Ashburn, VA, Quoin’s mission is to deliver the first approved therapies for conditions that currently have none. “We remain fully focused on delivering the first approved therapy for Netherton Syndrome,” said CEO Dr. Michael Myers globenewswire.com. The company’s pipeline comprises three main product candidates targeting multiple orphan indications finviz.com: Until recently, Quoin had additional assets (QRX004 for epidermolysis bullosa, and QRX007 for Netherton) but shelved those programs in mid-2025 to concentrate
11 October 2025
 ·  ·  ·  ·  · 
1 … 48 49 50 51 52 … 65
Go toTop